Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Moxibustion plus usual care vs sham moxibustion plus usual care Need for ECV ‐ not reported · breech presentation Cephalic version by moxibustion for breech presentation (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Clinical improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Histological improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Histological improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Endoscopic improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Endoscopic improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Endoscopic improvement at study endpoint (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Clinical improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Withdrawals due to adverse events at 26 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Histological improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
PGD2R antagonist OC000459 vs placebo Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
PGD2R antagonist OC000459 vs placebo Histological improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
PGD2R antagonist OC000459 vs placebo Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Swallowed fluticasone vs oral prednisone Clinical improvement at 4 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Swallowed fluticasone vs oral prednisone Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral viscous budesonide vs swallowed fluticasone Clinical improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral viscous budesonide vs swallowed fluticasone Endoscopic improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Histological improvement at study endpoint (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Endoscopic improvement at study endpoint (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs six‐food elimination diet Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs six‐food elimination diet Endoscopic improvement at study endpoint (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Clinical improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Endoscopic improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |